Price Chart

Executive Summary

Tarsus Pharmaceuticals announced an oversubscribed $125.0 million PIPE financing concurrent with its pending acquisition of Alkeus Pharmaceuticals. The company is selling 2,098,519 shares at $56.00/share and 133,625 pre-funded warrants at $55.9999 each to a syndicate including existing Alkeus investors (TCGX, Bain Capital Life Sciences, Wellington Management) and new/existing Tarsus investors. Proceeds will fund clinical development and commercial activities. The PIPE provides near-term funding certainty for the Alkeus acquisition and pipeline, but the ~9% dilution at a price below the prior close is a modest negative for existing holders.

Key Financial Metrics

Key Facts

• Gross proceeds of approximately $125.0 million from a PIPE financing.
• Sale of 2,098,519 shares of common stock at $56.00 per share and 133,625 pre-funded warrants at $55.9999 each.
• PIPE includes participation from existing Alkeus investors (TCGX, Bain Capital Life Sciences, Wellington Management) and new/existing Tarsus investors (ADAR1 Capital Management, Sirenia Capital Management, RTW Investments, Vestal Point Capital).
• PIPE is concurrent with the pending acquisition of Alkeus Pharmaceuticals, Inc. via a Merger Agreement dated July 31, 2026.
• Closing expected on August 7, 2026, subject to customary conditions.
• 90-day lock-up for company and directors/officers; company also restricted from issuing additional equity for 90 days.
• Registration Rights Agreement requires filing a resale registration statement by the earlier of (i) one day after Alkeus merger close + 40 days after receiving Alkeus financials, or (ii) termination of the Merger Agreement.
• Pre-funded warrants have a $0.0001 exercise price and a 4.99% (or 9.99% at holder election) beneficial ownership limitation.

Financial Impact

$125.0M gross proceeds from PIPE; dilution of ~9% based on ~2.23M new shares vs ~24.5M pre-offering shares outstanding (estimated from $2.6B market cap / $106 stock price).

Risk Factors

• Dilution of ~9% from the PIPE issuance.
• Risk that the Alkeus merger does not close, which would trigger different registration deadlines and potentially alter the use of proceeds.
• Potential for further dilution if pre-funded warrants are exercised (though minimal at $0.0001 exercise price).
• Market may view the PIPE as a signal that the company needed to raise capital to fund the Alkeus deal, potentially pressuring the stock.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status